Content area
Abstract
Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry is currently used in pathology for the assessment of melanocytic neoplasms; however, knowledge of its expression patterns in soft tissue tumors is limited. PRAME immunohistochemistry (clone QR005) was assessed on whole tissue sections of 350 soft-tissue tumors and mimics (> 50 histotypes). PRAME immunoreactivity was evaluated as follows: 0 “negative” (0% positive cells); 1+ (1–25% positive cells); 2+ (26–50% positive cells); 3+ (51–75% positive cells), and 4+ “diffuse” (> 75% positive cells). PRAME was expressed in 111 lesions (0 benign, 6 intermediate malignancy, and 105 malignant), including fibrosarcomatous dermatofibrosarcoma protuberans (2/4, 0 diffuse), NTRK-rearranged spindle cell neoplasm (2/4, 0 diffuse), atypical fibroxanthoma (1/7, 0 diffuse), Kaposi sarcoma (1/5, 0 diffuse), myxoid liposarcoma (11/11, 9 diffuse), synovial sarcoma (11/11, 6 diffuse), intimal sarcoma (7/7, 5 diffuse), biphenotypic sinonasal sarcoma (3/3, 1 diffuse), angiosarcoma (10/15, 6 diffuse), malignant peripheral nerve sheath tumor (9/12, 4 diffuse), pleomorphic rhabdomyosarcoma (2/3, 2 diffuse), alveolar rhabdomyosarcoma (2/6, 0 diffuse), embryonal rhabdomyosarcoma (7/7, 4 diffuse), undifferentiated pleomorphic sarcoma (2/12, 1 diffuse), leiomyosarcoma (2/15, 1 diffuse), clear cell sarcoma of soft tissue (1/10, 0 diffuse), low-grade fibromyxoid sarcoma (1/5, 0 diffuse), Ewing sarcoma (2/10, 1 diffuse), CIC-rearranged sarcoma (8/8, 4 diffuse), BCOR-sarcoma (2/5, 1 diffuse), melanoma (20/20, 14 diffuse), and thoracic SMARCA4-deficient undifferentiated tumor (5/5, all diffuse). All tested cases of spindle cell lipoma, dedifferentiated/pleomorphic liposarcoma, dermatofibrosarcoma protuberans, solitary fibrous tumor, inflammatory myofibroblastic tumor, myxoinflammatory fibroblastic sarcoma, nodular fasciitis, myxofibrosarcoma, epithelioid hemangioendothelioma, atypical vascular lesion, hemangioma, lymphangioma, vascular malformation, papillary endothelial hyperplasia, GIST, gastrointestinal clear-cell sarcoma, malignant melanotic nerve sheath tumor, neurofibroma, schwannoma, granular cell tumor, alveolar soft part sarcoma, epithelioid sarcoma, extraskeletal myxoid chondrosarcoma, myoepithelioma, ossifying fibromyxoid tumor, angiomatoid fibrous histiocytoma, PEComa, dermatofibroma, pleomorphic dermal sarcoma, and chordoma were negative. PRAME shows imperfect specificity in soft-tissue pathology but may serve as a diagnostic adjunct in selected differential diagnoses that show contrasting expression patterns.
Details
1 University of Bordeaux, Talence, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X); Institut Bergonié, Department of Biopathology, Bordeaux, France (GRID:grid.476460.7) (ISNI:0000 0004 0639 0505)
2 Bordeaux University Hospital, Department of Pathology, Bordeaux, France (GRID:grid.42399.35) (ISNI:0000 0004 0593 7118)
3 Charles University, Department of Pathology, Faculty of Medicine in Plzen, Pilsen, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X); Bioptical Laboratory Ltd., Plzen, Czech Republic (GRID:grid.485025.e)
4 Institut Bergonié, Department of Biopathology, Bordeaux, France (GRID:grid.476460.7) (ISNI:0000 0004 0639 0505)
5 University of Bordeaux, Talence, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X); Institut Bergonié, Department of Biopathology, Bordeaux, France (GRID:grid.476460.7) (ISNI:0000 0004 0639 0505); Institut Bergonié, INSERM U1218, ACTION, Bordeaux, France (GRID:grid.476460.7) (ISNI:0000 0004 0639 0505)
6 University of Bordeaux, Talence, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X); Bordeaux University Hospital, Department of Pathology, Bordeaux, France (GRID:grid.42399.35) (ISNI:0000 0004 0593 7118)
7 Institut Bergonié, Department of Biopathology, Bordeaux, France (GRID:grid.476460.7) (ISNI:0000 0004 0639 0505); Institut Bergonié, INSERM U1218, ACTION, Bordeaux, France (GRID:grid.476460.7) (ISNI:0000 0004 0639 0505)





